COVID-19 – Pipeline Analysis 2020 for Global Market

$2000$3920

Emphasis on Products covered by Phase (Phase III, Phase II, Phase I, Investigational New Drug, Pre-clinical, Discovery); Therapeutic Assessment by Stages (Product Type, Route of Administration, Molecule Type) and Company

Pages:

164

Table:

69

Figure:

26

Report ID:

UMHE20178

Geography:

Clear
  Get a Free Sample
SKU: UMHE20178 Categories: ,
Report Description
Table of content
Research Methodology

Report Description

COVID-19 - Pipeline 1
COVID-19 – Pipeline 1

COVID-19 (also known as Anderson COVID-19) is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other countries throughout the world. On March 11, 2020 World Health Organization (WHO) declared it a pandemic.

COVID-19 is mainly transmitted through contact with respiratory droplets rather than through the air and spreads primarily through contact with an infected person when they cough or sneeze. It also spreads when a person touches a surface or object that has the virus on it, then touches their eyes, nose, or mouth. A patient might take 1 to 14 days before developing symptoms as corona virus has an incubation period of 14 days. The most common symptoms of COVID-19 include dry cough, tiredness, fever and difficulty breathing (severe cases). Some patients may also suffer from aches and pains, runny nose, nasal congestion, sore throat or diarrhoea.

Split of Therapeutic Products

COVID-19 - Pipeline
COVID-19 – Pipeline

The diagnosis of the disease can be done by several methods such as nucleic acid test, serologic diagnosis and imaging technology. Chest radiograph or CT is an important tool for COVID-19 diagnosis in clinical practice. The majority of Covide-19 cases have similar features on CT images. Currently no antiviral treatment available for SARS-CoV-2 however, companies and research institutes are working towards it. Therapeutic agents targeting nucleosides, nucleotides, viral nucleic acids and enzymes/proteins involved in the replication and transcription of coronaviruses can be promising strategies to treat coronavirus diseases.

The pipeline of COVID-19 consists of approximately 85+ products in different stages of development. It includes therapeutic drugs and vaccines. Currently, 8+ drugs are in Phase III development and major drugs are in pre-clinical stage. Moreover, 42 vaccines are under development by various companies, and 2+ vaccines are in Phase I trial.

Top Company Analysed

Some of the key players include in the analysis includes Ascletis Pharma Inc., OncoImmune, FUJIFILM Toyama Chemical Co., Ltd.; Sanofi, Gilead Sciences, Incyte Corporation, Hoffmann La Roche, Vanda Pharmaceuticals, Apeiron Biologics and Relief Therapeutics Holdings among others.

Scope of the COVID-19 – Pipeline Analysis 2020:

  • The report provides an overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
  • The report comprises of detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
  • Listing of the vaccines under development by universities


Reasons to buy:

  • The COVID-19 pipeline report presents the detailed profile of drugs. The analysis offered in the report is a combination of deep dive secondary research and input from Key Opinion Leader of the industry
  • The report presents a quick review of the current scenario regarding the drug development of the indication at one glance
  • The report covers in-depth analysis of prominent industry peers with a primary focus on company consolidation, technology, agreements and patents regarding the therapy
  • Detailed examination on diagnosis and treatment prevailing in the industry
  • The study comprehensively covers the market across drugs in different phases of development


Customization Options:

The COVID-19 Pipeline analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

1.1Objective of the Study
 1.2Limitation 
 1.3Stakeholders 
 1.4Currency used in the Report
 1.5Secondary Research 
 1.6Scope of the COVID-19 – Pipeline Analysis Study
2.1Research Methodology for the COVID-19 – Pipeline Analysis 2020
 2.1.1Main objective of the COVID-19 – Pipeline Analysis 2020
3EXECUTIVE SUMMARY
4.1Introduction  
4.2Etiology  
4.3Virology  
 4.3.1Physicochemical Properties
 4.3.2Receptor Interactions and Cell Entry
4.4Diversity of Coronaviruses
4.5Epidemiology and clinical features of human coronaviruses
 4.5.1Source of Infection
 4.5.2Spectrum of Infection
 4.5.3Clinical Features
 4.5.4Epidemiological Characteristics in Mainland China and other countries
 4.5.5Herd Susceptibility
4.6Pathogenesis  
 4.6.1Virus Entry and Spread
 4.6.2Pathological Findings
 4.6.3Acute Respiratory Distress Syndrome (ARDS)
 4.6.4Cytokine Storm
 4.6.5Immune Dysfunction
4.7Signs and Symptoms  
4.8Diagnostic testing  
 4.8.1Nucleic Acid Test
 4.8.2Serologic Diagnosis
 4.8.3CRISPR/Cas13 System
 4.8.4Imaging Technology
4.9Treatment  
 4.9.1Type I IFNs 
 4.9.2Convalescent Plasma
 4.9.3Protective Monoclonal Antibody
 4.9.4Protease 
 4.9.5Others 
 4.9.6Vaccines 
 4.9.7Proposed COVID-19 Triage Algorithm for Low-income Settings Without Established Local Transmission
5.1General Overview (Clinical Stage Products)
5.2General Overview (Non-Clinical Stage Products
6CLINICAL PRODUCTS UNDER DEVELOPMENT BY TARGET
7.1General Overview
8.1Comparative Analysis
8.2ASC09+Ritonavir: Ascletis Pharmaceuticals Co., Ltd.
 8.2.1Product Description
 8.2.2Research and Development
  8.2.2.1Clinical Studies
   8.2.2.1.1
 8.2.3Product Development Activities
  8.2.3.1Collaboration
8.3CD24Fc: OncoImmune
 8.3.1Product Description
 8.3.2Research and Development
  8.3.2.1Clinical Studies
   8.3.2.1.1
8.4Favipiravir: FUJIFILM Toyama Chemical Co., Ltd.
 8.4.1Product Description
 8.4.2Research and Development
  8.4.2.1Clinical Studies
   8.4.2.1.1
8.5Hydroxychloroquine: Sanofi-Aventis
 8.5.1Product Description
 8.5.2Research and Development
  8.5.2.1Clinical Studies
   8.5.2.1.1
8.6Remdesivir: Gilead Sciences
 8.6.1Product Description
 8.6.2Research and Development
  8.6.2.1Pre-clinical Studies
  8.6.2.2Clinical Studies
   8.6.2.2.1
8.7Ruxolitinib: Incyte Corporation
 8.7.1Product Description
 8.7.2Research and Development
  8.7.2.1Clinical Studies
   8.7.2.1.1
 8.7.3Product Development Activities
  8.7.3.1Collaboration Agreement
8.8Tocilizumab: Hoffmann-La Roche
 8.8.1Product Description
 8.8.2Research and Development
  8.8.2.1Clinical Studies
   8.8.2.1.1
8.9Tradipitant: Vanda Pharmaceuticals
 8.9.1Product Description
 8.9.2Research and Development
  8.9.2.1Clinical Studies
   8.9.2.1.1
 8.9.3Product Development Activities
  8.9.3.1Licensing Agreement
  8.9.3.2Patent
9.1Comparative Analysis
9.2APN-01: Apeiron Biologics
 9.2.1Product Description
 9.2.2Research and Development
  9.2.2.1Clinical Studies
   9.2.2.1.1
 9.2.3Product Development Activities
  9.2.3.1Acquisition Agreement
9.3Aviptadil: Relief Therapeutics
 9.3.1Product Description
 9.3.2Research and Development
  9.3.2.1Clinical Studies
   9.3.2.1.1
 9.3.3Product Development Activities
  9.3.3.1Divestment Agreement
  9.3.3.2IND Application
  9.3.3.3Acquisition Agreement
9.4BXT-10: Bioxytran  
 9.4.1Product Description
 9.4.2Research and Development
  9.4.2.1Pre-clinical Studies
  9.4.2.2Clinical Studies
   9.4.2.2.1
 9.4.3Product Development Activities
  9.4.3.1Licensing
9.5Leronlimab: CytoDyn 
 9.5.1Product Description
 9.5.2Research and Development
  9.5.2.1Clinical Studies
   9.5.2.1.1
 9.5.3Product Development Activities
  9.5.3.1Acquisition Agreement
9.6Lopinavir+Ritonavir: AbbVie
 9.6.1Product Description
 9.6.2Research and Development
  9.6.2.1Clinical Studies
   9.6.2.1.1
 9.6.3Product Development Activities
  9.6.3.1Collaboration
9.7Plitidepsin: PharmaMar
 9.7.1Product Description
 9.7.2Research and Development
  9.7.2.1Preclinical Studies
  9.7.2.2Clinical Studies
   9.7.2.2.1
9.8Sarilumab: Sanofi-Aventis
 9.8.1Product Description
 9.8.2Research and Development
  9.8.2.1Clinical Studies
   9.8.2.1.1
 9.8.3Product Development Activities
  9.8.3.1Collaboration Agreement
  9.8.3.2Technology
9.9SNG001: Synairgen Research
 9.9.1Product Description
 9.9.2Research and Development
  9.9.2.1Clinical Studies
   9.9.2.1.1
 9.9.3Product Development Activities
  9.9.3.1Technology
10.1Comparative Analysis
10.2AmnioBoost: Lattice Biologics
 10.2.1Product Description
 10.2.2Research and Development
  10.2.2.1Clinical Studies
   10.2.2.1.1
10.3Baloxavir marboxil/Favipiravir and Lopinavir/Ritonavir: Shionogi & Co., Ltd.
 10.3.1Product Description
 10.3.2Research and Development
  10.3.2.1Clinical Studies
   10.3.2.1.1
10.4Gimsilumab: Roivant Sciences
 10.4.1Product Description
 10.4.2Research and Development
  10.4.2.1Clinical Studies
   10.4.2.1.1
10.5REGN3048+REGN3051: Regeneron Pharmaceuticals
 10.5.1Product Description
 10.5.2Research and Development
  10.5.2.1Pre-clinical Studies
  10.5.2.2Clinical Studies
   10.5.2.2.1
 10.5.3Product Development Activities
  10.5.3.1Collaboration Agreement
  10.5.3.2Technology
10.6Ifenprodil: Algernon Pharmaceuticals
 10.6.1Product Description
 10.6.2Research and Development
  10.6.2.1Pre-clinical Studies
  10.6.2.2Clinical Studies
   10.6.2.2.1
 10.6.3Product Development Activities
  10.6.3.1Recent Initiatives towards COVID-19 Pandemic
  10.6.3.2Manufacturing Agreement
  10.6.3.3IND Application
  10.6.3.4Contract Agreement
10.7Remestemcel-L: Mesoblast
 10.7.1Product Description
 10.7.2Research and Development
  10.7.2.1Clinical Studies
   10.7.2.1.1
 10.7.3Product Development Activities
  10.7.3.1IND Application
  10.7.3.2Partnership
  10.7.3.3Licensing Agreement
10.8TJM2: I-Mab Biopharma
 10.8.1Product Description
 10.8.2Research and Development
  10.8.2.1Clinical Studies
   10.8.2.1.1
 10.8.3Product Development Activities
  10.8.3.1IND Application
12.1Assessment by Stage and Product Type
12.2Assessment by Stage and Product Type
12.3Assessment by Route of Administration
12.4Assessment by Stage and Route of Administration
12.5Assessment by Molecule Type
12.6Assessment by Stage and Molecule Type
13EXECUTIVE SUMMARY
14.1Clinical Stage Vaccines
 14.2Ad5-nCoV: CanSino Biologics Inc.
 14.2.1Product Description
 14.2.2Research and Development
  14.2.2.1Pre-clinical Studies
  14.2.2.2Clinical Studies
   14.2.2.2.1
 14.2.3Product Development Activities
  14.2.3.1Technology
14.3mRNA-1273: Moderna Inc.
 14.3.1Product Description
 14.3.2Research and Development
  14.3.2.1Clinical Studies
   14.3.2.1.1
 14.3.3Product Development Activities
  14.3.3.1Funding
14.4INO-4800: Inovio Pharmaceuticals
 14.4.1Product Description
 14.4.2Research and Development
  14.4.2.1Pre-clinical Studies
  14.4.2.2Clinical Studies
   14.4.2.2.1
 14.4.3Product Development Activities
  14.4.3.1Collaboration
  14.4.3.2Funding
14.5Non-Clinical Stage Vaccines
15VACCINES UNDER DEVELOPMENT BY UNIVERSITIES

Research Methodology

Research Methodology for COVID-19 – Pipeline Analysis 2020

Overview of pipeline development activities for COVID-19 is not limited to drug description and development activities but also focuses on clinical and pre-clinical results. It also includes company collaboration, licensing deals, funds, and technology and patent details. Therapeutic segmentation of products for COVID-19 is done based on different stage of development. The report comprises of comparative pipeline therapeutics assessment along with detailed drug and vaccine profile of pipeline products by development stage, therapy type, molecule type, and administration route across this indication. Additionally, Executive summary have also been focused upon to give a summary regarding the current market scenario. The detailed profiles of the clinical vaccines products have been elucidated in the complete report and the non-clinical vaccines under development by companies and universities have also been listed.

Secondary Research

Detail secondary study was conducted to obtain the COVID-19 Pipeline Analysis through company internal sources such as quarterly reports, performance presentations, press releases, etc., and external sources including trade journals, news & articles, government publications, competitor publications, sector reports, regulatory body’s publications, safety standard organizations, third-party database and other creditable publications.

The secondary research on internal and external sources is being carried out to source qualitative and quantitative information relating to each market.

  • Company websites, quarterly reports, financial reports, broker reports, investor presentations and SEC filings
  • Industry trade journals and other literature
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market
  • Several databases for patents and clinical trials

Main objective of the COVID-19 – Pipeline Analysis 2020

The current pipeline trends of the COVID-19 are pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future pipeline trends would determine the overall attractiveness of the market, providing a platform for the industrial participant to exploit the untapped market to benefit as first mover advantage. The quantitative objectives for the report include:

  • Detailed overview of the indication including etiology, virology, diversity, pathogenesis, signs and symptoms, diagnostic testing and treatment algorithm
  • An overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
  • Analyse the detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
  • Therapeutic assessment of the clinical pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
  • Listing of the vaccines under development by universities